BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 26327694)

  • 1. Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits.
    Acosta-Alvear D; Cho MY; Wild T; Buchholz TJ; Lerner AG; Simakova O; Hahn J; Korde N; Landgren O; Maric I; Choudhary C; Walter P; Weissman JS; Kampmann M
    Elife; 2015 Sep; 4():e08153. PubMed ID: 26327694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
    Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
    Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The proteasome and proteasome inhibitors in multiple myeloma.
    Gandolfi S; Laubach JP; Hideshima T; Chauhan D; Anderson KC; Richardson PG
    Cancer Metastasis Rev; 2017 Dec; 36(4):561-584. PubMed ID: 29196868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.
    Besse A; Besse L; Kraus M; Mendez-Lopez M; Bader J; Xin BT; de Bruin G; Maurits E; Overkleeft HS; Driessen C
    Cell Chem Biol; 2019 Mar; 26(3):340-351.e3. PubMed ID: 30612952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells.
    Baranowska K; Misund K; Starheim KK; Holien T; Johansson I; Darvekar S; Buene G; Waage A; Bjørkøy G; Sundan A
    Oncotarget; 2016 Oct; 7(43):70845-70856. PubMed ID: 27683126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
    Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
    BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-Degrading Enzyme Is a Non Proteasomal Target of Carfilzomib and Affects the 20S Proteasome Inhibition by the Drug.
    Tundo GR; Sbardella D; Oddone F; Grasso G; Marini S; Atzori MG; Santoro AM; Milardi D; Bellia F; Macari G; Graziani G; Polticelli F; Cascio P; Parravano M; Coletta M
    Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy.
    Iannaccone A; Bruno G; Ravera A; Gay F; Salvini M; Bringhen S; Sabia L; Avenatti E; Veglio F; Milan A
    High Blood Press Cardiovasc Prev; 2018 Jun; 25(2):209-218. PubMed ID: 29582365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons Learned from Proteasome Inhibitors, the Paradigm for Targeting Protein Homeostasis in Cancer.
    Kambhampati S; Wiita AP
    Adv Exp Med Biol; 2020; 1243():147-162. PubMed ID: 32297217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines.
    Dettmer S; Theile D; Schäfer J; Seckinger A; Burhenne J; Weiss J
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Oct; 389(10):1091-101. PubMed ID: 27422413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.
    Lee SJ; Levitsky K; Parlati F; Bennett MK; Arastu-Kapur S; Kellerman L; Woo TF; Wong AF; Papadopoulos KP; Niesvizky R; Badros AZ; Vij R; Jagannath S; Siegel D; Wang M; Ahmann GJ; Kirk CJ
    Br J Haematol; 2016 Jun; 173(6):884-95. PubMed ID: 27071340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative mechanisms of action of proteasome inhibitors.
    Wang M
    Oncology (Williston Park); 2011 Nov; 25 Suppl 2():19-24. PubMed ID: 25188479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular effect and efficacy of carfilzomib depends on cellular net concentration gradient.
    Schäfer J; Welti L; Seckinger A; Burhenne J; Theile D; Weiss J
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):71-79. PubMed ID: 28500557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
    Steele JM
    J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.
    Stewart AK
    Future Oncol; 2015; 11(15):2121-36. PubMed ID: 26125319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs).
    Kuhn DJ; Orlowski RZ; Bjorklund CC
    Curr Cancer Drug Targets; 2011 Mar; 11(3):285-95. PubMed ID: 21247387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
    Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
    Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of carfilzomib in the treatment of multiple myeloma.
    Khan RZ; Badros A
    Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
    Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.